Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
14 studies found for:    PEYRONIE DISEASE
Show Display Options
Rank Status Study
1 Completed Peyronie's Disease Treatment Protocol
Condition: Peyronie's Disease
Interventions: Drug: H-100;   Drug: Placebo
2 Recruiting Management of Peyronie's Disease With Adipose Tissue Stem Cell
Conditions: Erectile Dysfunction;   Peyronie' Disease
Intervention: Drug: Adipose tissue stem cell injection
3 Completed
Has Results
Study of AA4500 in the Treatment of Peyronie's Disease
Condition: Peyronie's Disease
Interventions: Biological: AA4500;   Biological: Placebo
4 Completed
Has Results
Study of AA4500 in the Treatment of Peyronie's Disease
Condition: Peyronie's Disease
Interventions: Biological: AA4500;   Biological: Placebo
5 Completed
Has Results
A Study of AA4500 in Men With Peyronie's Disease
Condition: Peyronie's Disease
Intervention: Biological: AA4500
6 Completed
Has Results
The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease
Condition: Peyronie's Disease
Interventions: Biological: AA4500;   Biological: Placebo
7 Completed An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease
Condition: Peyronie's Disease
Interventions: Biological: AA4500;   Device: ErecAid® Esteem® Manual Vacuum Therapy System;   Procedure: Investigator Modeling
8 Completed
Has Results
A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
Condition: Peyronie's Disease
Intervention: Biological: AA4500
9 Recruiting H-22411: BOTOX® for Peyronie's Disease
Condition: Peyronie's Disease
Interventions: Drug: 100 units of Botulinum Toxin Type A;   Other: Preservative free normal saline
10 Completed
Has Results
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
Condition: Peyronie's Disease
Intervention: Biological: AA4500
11 Active, not recruiting Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease
Condition: Peyronie's Disease
Interventions: Drug: Vitamin D2;   Drug: Vitamin E;   Drug: Testosterone Pellets
12 Active, not recruiting Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Condition: Peyronie's Disease
Intervention: Drug: Subjects Previously Treated with AA4500
13 Completed Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD
Condition: Peyronie's Disease
Intervention: Biological: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)
14 Recruiting Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
Conditions: Neurodegenerative Diseases;   Osteoarthritis;   Erectile Dysfunction;   Autoimmune Diseases;   Cardiomyopathies;   Emphysema
Intervention: Procedure: Administration of autologous adipose derived SVF

Indicates status has not been verified in more than two years